Cognitive issues in Parkinson's disease

Neurologic Clinics

Volumn 22, Issue 3 SUPPL., 2004, Pages

  Elmer, Lawrence ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUETIAPINE; RIVASTIGMINE; SEDATIVE AGENT; SELEGILINE; TACRINE; TOCOPHEROL; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DELUSION; DEMENTIA; DISEASE EXACERBATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; IMAGING; LEWY BODY; LIFESPAN; LIVER TOXICITY; MOTOR DYSFUNCTION; NEUROPSYCHOLOGY; NURSING HOME; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; DIFFUSE LEWY BODY DISEASE; DRUG COMBINATION; DRUG INTERACTION; INTERVIEW; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; COGNITION DISORDERS; DEMENTIA; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LEWY BODY DISEASE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PARKINSON DISEASE;

EID: 16544382500     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.06.009     Document Type: Review

References (92)

1. D.J. Gelb, E. Oliver, and S. Gilman Diagnostic criteria for Parkinson disease Arch Neurol 56 1999 33 39
2. I.H. Richard, M. Papka, A. Rubio, and R. Kurlan Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 17 2002 1161 1165
3. M. Nussbaum, T.A. Treves, R. Inzelberg, J.M. Rabey, and A.D. Korczyn Survival in Parkinson's disease: the effect of dementia Pakinsonism Relat Disord 4 1998 179 181
4. M. Emre Dementia associated with Parkinson's disease Lancet Neurol 2 2003 229 237
5. M. Emre What causes mental dysfunction in Parkinson's disease? Mov Disord 18 2003 S63 S71
6. I. McKeith, J. Mintzer, D. Aarsland, D. Burn, H. Chiu, and J. Cohen-Mansfield Dementia with Lewy bodies Lancet Neurol 3 2004 19 28
7. C.H. Waters Treatment of advanced stage patients with Parkinson's disease Parkinsonism Relat Disord 9 2002 15 21
8. A.A. Rabinstein, and L.M. Shulman Management of behavioral and psychiatric problems in Parkinson's disease Parkinsonism Relat Disord 7 2001 41 50
9. E.C. Wolters Intrinsic and extrinsic psychosis in Parkinson's disease J Neurol 248 Suppl 3 2001 III-22 III-27
10. E. Noe, K. Marder, K.L. Bell, D.M. Jacobs, J.J. Manly, and Y. Stern Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia Mov Disord 19 2004 60 67
11. E. Iseki Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease Neuropathology 24 2004 72 78
12. A.D. Korczyn Dementia in Parkinson's disease J Neurol 248 Suppl 3 2001 III-1 III-4
13. W. Poewe Psychosis in Parkinson's disease Mov Disord 18 Suppl 6 2003 S80 S87
14. T.A. Hughes, H.F. Ross, S. Musa, S. Bhattacherjee, R.N. Nathan, and R.H. Mindham A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease Neurology 54 2000 1596 1602
15. D. Aarsland, K. Andersen, J.P. Larsen, A. Lolk, and P. Kragh-Sørensen Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study Arch Neurol 60 2003 387 392
16. R. Mayeux, J. Chen, E. Mirabello, K. Marder, K. Bell, and G. Dooneief An estimate of the incidence of dementia in idiopathic Parkinson's disease Neurology 40 1990 1513 1517
17. J.A. Cooper, H.J. Sagar, N. Jordan, N.S. Harvey, and E.V. Sullivan Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability Brain 114 1991 2095 2122
18. G. Levy, N. Schupf, M.X. Tang, L.J. Cote, E.D. Louis, and H. Mejia Combined effect of age and severity on the risk of dementia in Parkinson's disease Ann Neurol 51 2002 722 729
19. H. Apaydin, J.E. Ahlskog, J.E. Parisi, B.F. Boeve, and D.W. Dickson Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response Arch Neurol 59 2002 102 112
20. J.L. Cummings Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates J Geriatr Psychiatry Neurol 1 1988 24 36
21. I.G. McKeith, D. Galasko, K. Kosaka, E.K. Perry, D.W. Dickson, and L.A. Hansen Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology 47 1996 1113 1124
22. K.M. Mattila, J.O. Rinne, M. Roytta, P. Laippala, T. Pietila, and H. Kalimo Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology J Med Genet 37 2000 766 770
23. Y. Trembath, C. Rosenberg, J.F. Ervin, D.E. Schmechel, P. Gaskell, and M. Pericak-Vance Lewy body pathology is a frequent co-pathology in familial Alzheimer's disease Acta Neuropathol (Berl) 105 2003 484 488
24. K.A. Jellinger, K. Seppi, G.K. Wenning, and W. Poewe Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease J Neural Transm 109 2002 329 339
25. A.J. Harding, and G.M. Halliday Cortical Lewy body pathology in the diagnosis of dementia Acta Neuropathol (Berl) 102 2001 355 363
26. E. Londos, U. Passant, L. Gustafson, and A. Brun Neuropathological correlates to clinically defined dementia with Lewy bodies Int J Geriatr Psychiatry 16 2001 667 669
27. H.I. Hurtig, J.Q. Trojanowski, J. Galvin, D. Ewbank, M.L. Schmidt, and V.M.-Y Lee Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease Neurology 54 2000 1916 1921
28. Z. Walker, R.L. Allen, S. Shergill, E. Mullan, and C.L. Katona Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies Int J Geriatr Psychiatry 15 2000 267 273
29. O.L. Lopez, R.L. Hamilton, J.T. Becker, S. Wisniewski, D.I. Kaufer, and S.T. DeKosky Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies Neurology 54 2000 1780 1787
30. G. Levy, M.-X Tang, E.D. Louis, L.J. Cote, B. Alfaro, and M.A. Mejia The association of incident dementia with mortality in PD Neurology 59 2002 1708 1713
31. J.G. Greenfield, and F.D. Bosanquet The brain stem lesions in parkinsonism J Neurol Neurosurg Psychiatry 16 1953 213 226
32. W.R.G. Gibb, T. Scott, and A.J. Lees Neuronal inclusions of Parkinson's disease Mov Disord 6 1991 2 11
33. J.E. Duda, B.I. Giasson, Q. Chen, T.L. Gur, H.I. Hurtig, and M.B. Stern Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies Am J Pathol 157 2000 1439 1445
34. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies Proc Natl Acad Sci U S A 95 1998 6469 6473
35. K.S. McNaught, P. Shashidharan, D.P. Perl, P. Jenner, and C.W. Olanow Aggresome-related biogenesis of Lewy bodies Eur J Neurosci 16 2002 2136 2148
36. Y. Furukawa, S. Vigouroux, H. Wong, M. Guttman, A.H. Rajput, and L. Ang Brain proteasomal function in sporadic Parkinson's disease and related disorders Ann Neurol 51 2002 779 782
37. C. Zarow, S.A. Lyness, J.A. Mortimer, and H.C. Chui Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases Arch Neurol 60 2003 337 341
38. L. Hansen, D. Salmon, D. Galasko, E. Masliah, R. Katzman, and R. DeTeresa The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity Neurology 40 1990 1 8
39. G. Lennox, J. Lowe, K. Morrell, M. Landon, and R.J. Mayer Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease J Neurol Neurosurg Psychiatry 52 1989 67 71
40. A.J. Hughes, S.E. Daniel, S. Blankson, and A.J. Lees A clinicopathologic study of 100 cases of Parkinson's disease Arch Neurol 50 1993 140 148
41. K. Jendroska, A.J. Lees, W. Poewe, and S.E. Daniel Amyloid β-peptide and the dementia of Parkinson's disease Mov Disord 11 1996 647 653
42. V. Haroutunian, M. Serby, D.P. Purohit, D.P. Perl, D. Marin, and M. Lantz Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions Arch Neurol 57 2000 1145 1150
43. I.G. McKeith Dementia with Lewy bodies Br J Psychiatry 180 2002 144 147
44. T.A. Ala, L.F. Hughes, G.A. Kyrouac, M.W. Ghobrial, and R.J. Elble The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease Int J Geriatr Psychiatry 17 2002 503 509
45. Y. Horimoto, M. Matsumoto, H. Nakazawa, H. Yuasa, M. Morishita, and H. Akatsu Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia J Neurol Sci 216 2003 105 108
46. E. Rockwell, J. Choure, D. Galasko, J. Olichney, and D.V. Jeste Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses Int J Geriatr Psychiatry 15 2000 819 823
47. J.B. Grace, M.P. Walker, and I.G. McKeith A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease Int J Geriatr Psychiatry 15 2000 1028 1033
48. B.F. Boeve, M.H. Silber, T.J. Ferman, J.A. Lucas, and J.E. Parisi Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy Mov Disord 16 2001 622 630
49. R.L. Albin, S. Minoshima, C.J. D'Amato, K.A. Frey, D.A. Kuhl, and A.A. Sima Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease Neurology 47 1996 462 466
50. S. Minoshima, N.L. Foster, A.A. Sima, K.A. Frey, R.L. Albin, and D.E. Kuhl Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation Ann Neurol 50 2001 358 365
51. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease Eur J Nucl Med 24 1997 320 325
52. T. Imamura, K. Ishii, M. Sasaki, H. Kitagaki, S. Yamaji, and N. Hirono Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography Neurosci Lett 235 1997 49 52
53. M.J. Firbank, S.J. Colloby, D.J. Burn, I.G. McKeith, and J.T. O'Brien Regional cerebral blood flow in Parkinson's disease with and without dementia Neuroimage 20 2003 1309 1319
54. N.I. Bohnen, D.I. Kaufer, L.S. Ivanco, B. Lopresti, R.A. Koeppe, and J.G. Davis Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch Neurol 60 2003 1745 1748
55. C. Johnson Ensuring home safety for your Alzheimer's patients Adv Nurse Pract 10 2002 65
56. J.M. Hausdorff, J. Balash, and N. Giladi Effects of cognitive challenge on gait variability in patients with Parkinson's disease J Geriatr Psychiatry Neurol 16 2003 53 58
57. T.C. Rubinstein, N. Giladi, and J.M. Hausdorff The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease Mov Disord 17 2002 1148 1160
58. W.J. Weiner, and C. Singer Parkinson's disease and nonpharmacologic treatment programs J Am Geriatr Soc 37 1989 359 363
59. C.W. Olanow, R.L. Watts, and W.C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines Neurology 56 Suppl 5 2001 S1 S88
60. D.J. Burn, and I.G. McKeith Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease Mov Disord 18 Suppl 6 2003 S72 S79
61. J.H. Friedman, and H.H. Fernandez Atypical antipsychotics in Parkinson-sensitive populations J Geriatr Psychiatry Neurol 15 2002 156 170
62. S.A. Factor, J.H. Friedman, M.C. Lannon, D. Oakes, K. Bourgeois, and for the Parkinson Study Group Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial Mov Disord 16 2001 135 139
63. H.H. Fernandez, M.C. Lannon, J.H. Friedman, and B.P. Abbott Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease Mov Disord 15 2000 579 581
64. F. Lebert, F. Pasquier, L. Soulez, and H. Petit Tacrine efficacy in Lewy body dementia Int J Geriatr Psychiatry 13 1998 516 519
65. S.L. Rogers, R.S. Doody, R.C. Mohs, L.T. Friedhoff, and for the Donepezil Study Group Donepezil improves cognition and global function in Alzheimer disease Arch Intern Med 158 1998 1021 1031
66. R.C. Mohs, R.S. Doody, J.C. Morris, J.R. Ieni, S.L. Rogers, and C.A. Perdomo A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 2001 481 488
67. B. Winblad, K. Engedal, H. Soininen, F. Verhey, G. Waldemar, and A. Wimo A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 57 2001 489 495
68. M. Farlow, R. Anand, J. Messina Jr., R. Hartman, and J. Veach A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease Eur Neurol 44 2000 236 241
69. M.A. Raskind, E.R. Peskind, T. Wessel, W. Yuan, and for the Galantamine USA-1 Study Group Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension Neurology 54 2000 2261 2268
70. M. Hutchinson, and E. Fazzini Cholinesterase inhibition in Parkinson's disease [letter] J Neurol Neurosurg Psychiatry 61 1996 324 325
71. M. Galisteo, M. Rissel, O. Sergent, M. Chevanne, J. Cillard, and A. Guillouzo Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation J Pharmacol Exp Ther 294 2000 160 167
72. D. Aarsland, K. Brønnick, and K. Karlsen Donepezil for dementia with Lewy bodies: a case study Int J Geriatr Psychiatry 14 1999 69 72
73. E. Fergusson, and R. Howard Donepezil for the treatment of psychosis in dementia with Lewy bodies Int J Geriatr Psychiatry 15 2000 280 281
74. D. Aarsland, J.P. Larsen, C. Janvin, and K. Laake Donepezil treatment in Parkinson's disease with dementia: a double-blind, placebo-controlled crossover study J Neurol Neurosurg Psychiatry 72 2002 708 712
75. E.A. Werber, and J.M. Rabey The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia J Neural Transm 108 2001 1319 1325
76. I.G. McKeith, J.B. Grace, Z. Walker, E.J. Byrne, D. Wilkinson, and T. Stevens Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial Int J Geriatr Psychiatry 15 2000 387 392
77. N. Giladi, H. Shabtai, T. Gurevich, B. Benbunan, M. Anca, and A.D. Korczyn Rivastigmine (Exelon) for dementia in patients with Parkinson's disease Acta Neurol Scand 108 2003 368 373
78. G. Fabbrini, P. Barbanti, C. Aurilia, C. Pauletti, G.L. Lenzi, and G. Meco Donepezil in the treatment of hallucinations and delusions in Parkinson's disease Neurol Sci 23 2002 41 43
79. K.L. Lanctôt, and N. Herrmann Donepezil for behavioural disorders associated with Lewy bodies: a case series Int J Geriatr Psychiatry 15 2000 338 345
80. J. Bergman, and V. Lerner Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease Clin Neuropharmacol 25 2002 107 110
81. D. Aarsland, M. Hutchinson, and J.P. Larsen Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia Int J Geriatr Psychiatry 18 2003 937 941
82. I. McKeith, T. Del Sur, P. Spano, M. Emre, K. Wesnes, and R. Anand Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo controlled international study Lancet 356 2000 2031 2036
83. B. Reisberg, R. Doody, A. Stöffler, F. Schmitt, S. Ferris, H.J. Möbius, and for the Memantine Study Group Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 2003 1333 1341
84. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald, and I. Gergel Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA 291 2004 317 324
85. C.G. Goetz, and G.T. Stebbins Risk factors for nursing home placement in advanced Parkinson's disease Neurology 43 1993 2227 2229
86. C.G. Goetz, and G.T. Stebbins Mortality and hallucinations in nursing home patients with advanced Parkinson's disease Neurology 45 1995 669 671
87. M.F. Lew, and C.H. Waters Parkinsonism with psychosis J Am Geriatr Soc 41 1993 669 671
88. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO study Arch Neurol 59 2002 1937 1943
89. S. Reddy, S.A. Factor, E.S. Molho, and P.J. Feustel The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia Mov Disord 17 2002 676 681
90. H.H. Fernandez, M.E. Trieschmann, M.A. Burke, C. Jacques, and J.H. Friedman Long-term outcome of quetiapine use for psychosis among parkinsonian patients Mov Disord 18 2003 510 514
91. K. Marder, M.X. Tang, B. Alfaro, H. Mejia, L. Cote, and D. Jacobs Postmenopausal estrogen use and Parkinson's disease with and without dementia Neurology 50 1998 1141 1143
92. K. Kieburtz, M. McDermott, P. Como, J. Growdon, J. Brady, and J. Carter for the Parkinson Study Group The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease Neurology 44 1994 1756 1759